Contrasting Talphera (NASDAQ:TLPH) and ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ:ANIP) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Insider and Institutional Ownership

76.0% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of Talphera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

ANI Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Talphera has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.

Profitability

This table compares ANI Pharmaceuticals and Talphera’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Talphera	N/A	-87.28%	-51.36%

Analyst Ratings

This is a summary of recent ratings and recommmendations for ANI Pharmaceuticals and Talphera, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0	4	3	0	2.43
Talphera	1	1	2	0	2.25

ANI Pharmaceuticals currently has a consensus price target of $99.60, suggesting a potential upside of 38.37%. Talphera has a consensus price target of $3.00, suggesting a potential upside of 177.78%. Given Talphera’s higher probable upside, analysts clearly believe Talphera is more favorable than ANI Pharmaceuticals.

Valuation and Earnings

This table compares ANI Pharmaceuticals and Talphera”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37 million	1.87	$78.34 million	$4.64	15.51
Talphera	$30,000.00	1,868.76	-$14.29 million	($0.27)	-4.00

ANI Pharmaceuticals has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

ANI Pharmaceuticals beats Talphera on 11 of the 14 factors compared between the two stocks.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

About Talphera

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.